{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T08:11:40Z","timestamp":1794471100460,"version":"4.9.1"},"reference-count":17,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T00:00:00Z","timestamp":1729555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Merck Sharp &amp; Dohme LLC"},{"name":"Merck &amp; Co., Inc., Rahway, NJ, USA"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Although data on patients treated with pembrolizumab are available from clinical trials and single-country real-world reports, to our knowledge no multi-country real-world studies have investigated the use of pembrolizumab as an adjuvant treatment for stage III melanoma. Methods: We used the European Melanoma Registry (EUMelaReg), a disease entity-based registry specific for melanoma, to examine treatment and outcomes for adult patients with stage III melanoma with lymph node involvement who had complete resection and received adjuvant treatment with pembrolizumab. The primary objectives were to describe the demographic and clinical characteristics of the included patients as well as time on adjuvant pembrolizumab treatment (TOT), real-world recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) from adjuvant pembrolizumab initiation. Secondary objectives were time to next treatment (TTNT) after adjuvant use of pembrolizumab, next-line therapy for stage III and unresectable stage IV melanoma and overall survival (OS) from initiation of pembrolizumab. Results: Patients were stratified according to age, sex, BRAF status, number of positive lymph nodes and disease substage. Median TOT was 11.1 (9.2\u201311.5) months, median RFS was 29.6 [18.7\u2013not reached (NR)] months and median DMFS was 32.4 (22.7\u2013NR) months. TTNT was 29.9 (22.2\u2013NR) months, while median OS was not reached. Conclusions: The results of this study offer insights into the real-world use of pembrolizumab as an adjuvant therapy for melanoma in Europe.<\/jats:p>","DOI":"10.3390\/cancers16213558","type":"journal-article","created":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T06:11:25Z","timestamp":1729577485000},"page":"3558","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Adjuvant Use of Pembrolizumab for Stage III Melanoma in a Real-World Setting in Europe"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9060-4961","authenticated-orcid":false,"given":"Michael","family":"Weichenthal","sequence":"first","affiliation":[{"name":"Skin Cancer Center Kiel, University Hospital Schleswig-Holstein, 24105 Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Mangana","sequence":"additional","affiliation":[{"name":"University Hospital of Zurich, 8091 Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iva","family":"Gavrilova","sequence":"additional","affiliation":[{"name":"National Oncology Hospital Sofia, g.k. Darvenitsa, 1756 Sofia, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9511-178X","authenticated-orcid":false,"given":"Iwona","family":"Lugowska","sequence":"additional","affiliation":[{"name":"Instytut im. Marii Sk\u0142odowskiej-Curie, 02-781 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gergana Krumova","family":"Shalamanova","sequence":"additional","affiliation":[{"name":"Complex Oncology Center Plovdiv, 4004 Plovdiv, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5221-5068","authenticated-orcid":false,"given":"Lidija","family":"Kandolf","sequence":"additional","affiliation":[{"name":"Military Medical Academy (CSEEMEG), 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanna","family":"Chiarion-Sileni","sequence":"additional","affiliation":[{"name":"Istituto Oncologico Veneto, IOV-IRCCS, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Mohr","sequence":"additional","affiliation":[{"name":"Elbe Kliniken Buxtehude-Stade, 21614 Buxtehude, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teodora Sotirova","family":"Karanikolova","sequence":"additional","affiliation":[{"name":"Nadezhda Hospital, 1330 Sofia, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7304-714X","authenticated-orcid":false,"given":"Pawel","family":"Teterycz","sequence":"additional","affiliation":[{"name":"Instytut im. Marii Sk\u0142odowskiej-Curie, 02-781 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Espinosa","sequence":"additional","affiliation":[{"name":"Hospital Universitario La Paz, 28046 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Schnecko","sequence":"additional","affiliation":[{"name":"Alcedis GmbH, 35394 Gie\u00dfen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2940-006X","authenticated-orcid":false,"given":"Phil","family":"Cheng","sequence":"additional","affiliation":[{"name":"University Hospital of Zurich, 8091 Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2304-1473","authenticated-orcid":false,"given":"Marc","family":"Bender","sequence":"additional","affiliation":[{"name":"Skin Cancer Center, Division of Molecular Cell Biology, Elbe Kliniken Stade-Buxtehude, 21614 Buxtehude, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Jiang","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Rahway, NJ 07065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Burke","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Rahway, NJ 07065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo Antonio","family":"Ascierto","sequence":"additional","affiliation":[{"name":"Melanoma and Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione \u201cG. Pascale\u201d, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0451-2885","authenticated-orcid":false,"given":"Helen","family":"Gogas","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, Laikon General Hospital, School of Medicine, University of Athens, 15772 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2476-668X","authenticated-orcid":false,"given":"Ivan Marquez","family":"Rodas","sequence":"additional","affiliation":[{"name":"Hospital General Universitario Gregorio Mara\u00f1\u00f3n, 28007 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8920-5429","authenticated-orcid":false,"given":"Piotr","family":"Rutkowski","sequence":"additional","affiliation":[{"name":"Instytut im. Marii Sk\u0142odowskiej-Curie, 02-781 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3524-7858","authenticated-orcid":false,"given":"Dirk","family":"Schadendorf","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum, 45147 Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2279-6906","authenticated-orcid":false,"given":"Reinhard","family":"Dummer","sequence":"additional","affiliation":[{"name":"University Hospital of Zurich, 8091 Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the EUMelaReg Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Balch, C.M., Atkins, M.B., Garbe, C., Gershenwald, J.E., Halpern, A.C., Kirkwood, J.M., McArthur, G.A., Thompson, J.F., and Sober, A.J. (2020). Clinical Epidemiology of Melanoma. Cutaneous Melanoma, Springer International Publishing.","DOI":"10.1007\/978-3-319-46029-1"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/ijc.33266","article-title":"Metastatic melanoma patient outcomes since introduction of immune checkpoint inhibitors in England between 2014 and 2018","volume":"148","author":"Board","year":"2020","journal-title":"Int. J. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"290","DOI":"10.6004\/jnccn.2024.0036","article-title":"NCCN Guidelines\u00ae Insights: Melanoma: Cutaneous, Version 2.2024","volume":"22","author":"Swetter","year":"2024","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"104276","DOI":"10.1016\/j.critrevonc.2024.104276","article-title":"The treatment of advanced melanoma: Current approaches and new challenges","volume":"196","author":"Boutros","year":"2024","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ejca.2019.05.020","article-title":"Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325\/KEYNOTE-054 trial of pembrolizumab vs lacebo in resected high-risk stage III melanoma","volume":"116","author":"Eggermont","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_9","first-page":"EVIDoa2200214","article-title":"Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma","volume":"1","author":"Eggermont","year":"2022","journal-title":"NEJM \u00c9vid."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ejca.2018.01.084","article-title":"Is low survival for cancer in Eastern Europe due principally to late stage at diagnosis?","volume":"93","author":"Minicozzi","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ejca.2018.09.013","article-title":"Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries","volume":"104","author":"Sekulovic","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"viii459","DOI":"10.1093\/annonc\/mdy289.042","article-title":"EUMelaReg: A European platform for outcome research on real world treatment data of patients with advanced melanoma","volume":"29","author":"Weichenthal","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejca.2016.12.017","article-title":"The majority of patients with metastatic melanoma are not represented in pivotal phase III immunotherapy trials","volume":"74","author":"Donia","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e16542","DOI":"10.1097\/MD.0000000000016542","article-title":"Real-world experience with pembrolizumab in patients with advanced melanoma: A large retrospective observational study","volume":"98","author":"Liu","year":"2019","journal-title":"Medicine"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/CJI.0000000000000204","article-title":"Pembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practices","volume":"41","author":"Cowey","year":"2018","journal-title":"J. Immunother."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Cowey, C.L., Sura, S., Beeks, A., Scherrer, E., Krepler, C., and Jiang, R. (2021, January 28\u201331). Real-world outcomes of adjuvant pembrolizumab for completely resected stage III cutaneous melanoma. Proceedings of the 18th International Congress of the Society for Melanoma Research (SMR), Virtual.","DOI":"10.1016\/j.annonc.2020.08.1239"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S1470-2045(20)30062-0","article-title":"Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF(V600)-mutant, stage III melanoma (COMBI-AD): Exploratory biomarker analyses from a randomised, phase 3 trial","volume":"21","author":"Dummer","year":"2020","journal-title":"Lancet Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/21\/3558\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:17:46Z","timestamp":1760113066000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/21\/3558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,22]]},"references-count":17,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["cancers16213558"],"URL":"https:\/\/doi.org\/10.3390\/cancers16213558","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,22]]}}}